|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,954.10 INR | -2.52% |
|
-1.27% | +6.69% |
| 02-25 | Indo Borax & Chemicals Limited Appoints Shashikant Bharuka as the Chief Financial Officer Effective March 6, 2026 | CI |
| 02-10 | Ajanta Pharma Ltd issues clarification on media report | RE |
| Capitalization | 369B 4B 3.48B 3.15B 3.01B 5.47B 5.67B 37.45B 14.88B 177B 15B 14.68B 637B | P/E ratio 2026 * |
34.8x | P/E ratio 2027 * | 29.7x |
|---|---|---|---|---|---|
| Enterprise value | 360B 3.9B 3.4B 3.08B 2.94B 5.34B 5.54B 36.56B 14.53B 172B 14.64B 14.33B 622B | EV / Sales 2026 * |
6.7x | EV / Sales 2027 * | 5.9x |
| Free-Float |
33.52% | Yield 2026 * |
1.13% | Yield 2027 * | 1.3% |
Last Transcript: Ajanta Pharma Limited
| 1 day | -2.52% | ||
| 1 week | -1.27% | ||
| Current month | -1.33% | ||
| 1 month | +1.16% | ||
| 3 months | +11.81% | ||
| 6 months | +15.87% | ||
| Current year | +6.69% |
| 1 week | 2,930 |  | 3,228 |
| 1 month | 2,830 | | 3,228 |
| Current year | 2,654.5 | | 3,228 |
| 1 year | 2,327.3 | | 3,228 |
| 3 years | 1,131.7 | | 3,485 |
| 5 years | 1,061.77 | | 3,485 |
| 10 years | 550 | | 3,485 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | - | |
| Chief Executive Officer | 54 | 20/12/2009 | |
| Director of Finance/CFO | 61 | 22/04/1998 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 54 | 31/12/1995 | |
| Chairman | 79 | 30/12/1979 | |
| Director/Board Member | 71 | 20/12/2009 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.52% | -1.27% | +16.38% | +146.37% | 4.09B | |
| -1.02% | -0.90% | +5.93% | +87.43% | 46.73B | |
| -0.55% | +8.80% | +43.67% | +175.48% | 36.39B | |
| -5.44% | -4.45% | +281.40% | +1,295.79% | 11.97B | |
| -1.12% | -1.60% | -11.07% | +48.07% | 11.48B | |
| -2.10% | -2.86% | +0.43% | +87.35% | 9.86B | |
| +5.65% | +8.94% | +79.18% | +54.91% | 8.47B | |
| +0.87% | +0.87% | +38.10% | +123.08% | 7.98B | |
| -0.97% | -7.18% | +43.12% | -17.12% | 6.96B | |
| +0.22% | +2.40% | +54.82% | +408.09% | 6.62B | |
| Average | -0.70% | +0.17% | +55.20% | +240.95% | 15.06B | |
| Weighted average by Cap. | -0.84% | +1.68% | +45.28% | +212.72% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 53.75B 582M 507M 459M 438M 797M 826M 5.46B 2.17B 25.72B 2.18B 2.14B 92.75B | 60.84B 659M 574M 520M 496M 902M 935M 6.18B 2.45B 29.11B 2.47B 2.42B 105B |
| Net income | 10.62B 115M 100M 90.75M 86.57M 157M 163M 1.08B 428M 5.08B 432M 423M 18.33B | 12.47B 135M 118M 106M 102M 185M 192M 1.27B 503M 5.96B 507M 496M 21.51B |
| Net Debt | -8.74B -94.72M -82.51M -74.7M -71.27M -130M -134M -888M -353M -4.18B -355M -348M -15.09B | -9.86B -107M -93.02M -84.22M -80.35M -146M -152M -1B -398M -4.72B -401M -392M -17.01B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/03/26 | 2,954.10 ₹ | -2.52% | 186,235 |
| 13/03/26 | 3,030.60 ₹ | -2.85% | 154,564 |
| 12/03/26 | 3,119.50 ₹ | +2.34% | 297,692 |
| 11/03/26 | 3,048.20 ₹ | +1.61% | 106,740 |
| 10/03/26 | 2,999.90 ₹ | +2.16% | 123,027 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AJANTPHARM Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition